OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Investigational Drugs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Navafenterol for chronic obstructive pulmonary disease therapy	92
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?	85
Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials	80
Novel experimental and early investigational drugs for the treatment of bipolar disorder	78
JAK inhibitors for rheumatoid arthritis	75
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects	69
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer	69
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	64
Investigational drugs for HIV: trends, opportunities and key players	58
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	51
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia	48
Targeting leukemia inhibitory factor in pancreatic adenocarcinoma	42
The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized stu	41
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development	41
A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a nov	39
Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma	34
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	33
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	32
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	32
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies	31
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	30
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	29
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?	29
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	28
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	26